ReviewTranslational lung cancer research2013
ALK and ROS1 as a joint target for the treatment of lung cancer: a review.
Review in Translational lung cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- The role of BLZF1 in lung adenocarcinoma and its value as a diagnostic and prognostic biomarker.Scientific reports · 2026Article
- Visceral crisis in a patient with non-small cell lung cancer andTranslational lung cancer research · 2025Article
- Identification of key LncRNAs and mRNAs associated with intramuscular fat in pig via WGCNA.BMC genomics · 2025Article
- Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants.Cancer biology & medicine · 2024Review
- QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads.Molecules (Basel, Switzerland) · 2022Article
- Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer's disease.Frontiers in aging neuroscience · 2022Article
- Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.Drug safety · 2021Article
- Therapeutic Sequencing in ALKPharmaceuticals (Basel, Switzerland) · 2021Review
- R-spondin family members as novel biomarkers and prognostic factors in lung cancer.Oncology letters · 2019Article
- Efficacy and safety of crizotinib in patients withJournal of thoracic disease · 2019Article
- Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Crizotinib induces apoptosis of lung cancer cells through JAK-STAT pathway.Oncology letters · 2018Article
- Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Expert review of molecular diagnostics · 2016Review
- ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.Oncotarget · 2016Review
- Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.Journal of experimental pharmacology · 2016Article
- Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Cancer chemotherapy and pharmacology · 2014Review
- Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.Cancer biology & medicine · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rearrangements of the anaplastic lymphoma kinase (ALK) have been described in multiple malignancies, including non-small cell lung cancer (NSCLC). ALK fusions have gain of function properties while activating mutations in wild-type ALK can also occur within the tyrosine kinase domain. ALK rearrangements define a new molecular subtype of NSCLC that is exquisitely sensitive to ALK inhibition. Crizotinib, an orally available small molecule ATP-mimetic compound which was originally designed as a MET inhibitor, was recognized to have "off-target" anti-ALK activity and has been approved in the USA for the treatment of patients with ALK-positive NSCLC. Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase have also been recently described in NSCLC, while crizotinib is currently under clinical trial in this molecular subset of NSCLC patients. The basic approaches of any computer aided drug design work in terms of structure and ligand based drug design. Details of each of these approaches should be covered with an emphasis on utilizing both in order to develop multi-targeted small-molecule kinase inhibitors. Such multi-targeted tyrosine kinase inhibitors can have antiproliferative activity against both ROS1and ALK rearranged NSCLC. Herein, we highlight the importance of targeting these proteins and the advances in optimizing more potent and selective ALK and ROS1 kinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.